T CELLS AS THERAPEUTIC TARGETS

Much of our experience with biological agents in autoimmune disease has been derived from studies of T cell directed therapy in rheumatoid arthritis (RA) (box 1). Data from these studies have provided substantial insight into study design, product development, and T cell biology. Initial studies entailed targeting of CD4 T cells with murine monoclonal antibodies (mAb) of differing isotypes directed at a variety of epitopes on the CD4 molecule. Between 1989–1994, eight short-term open label trials yielded promising results with clinical responses in 60%–75% of patients (reviewed in Strand and Keystone).1 In 1996, seven years after the initial studies were published, the first randomised placebo controlled trial (RCT) of murine anti-CD4 mAb showing no clinical benefit was reported.2 A similar discrepancy in clinical outcome between early uncontrolled trials and placebo RCTs was also observed with a murine anti-CD5 immunotoxin conjugate,3 as well as the chimeric anti-CD4 mAb, cM412.4,5 This difference probably reflects both expectation bias on the part of the investigator and patient with “new and innovative therapy” as well as a placebo effect. In studies of anti-CD5 immunotoxin conjugate, for example a placebo rate as high 50% was observed. A review of the problem by Epstein suggested that the results reflect more of an expectation bias than a placebo effect.6 His conclusion is based on an analysis of several trials involving chimeric anti-CD4 mAb in which the clinical benefit observed in the experimental group of the RCT was significantly lower than that observed in the open label groups. A placebo effect would be expected to yield comparable clinical responses between the two groups. The discrepancy between open label and RCT responses emphasises the magnitude of experimental bias in open label studies and as well as the need for vigorous blinding in RCTs. The data suggest that the use of a placebo group in early phase I/II studies would provide a reality check for our sometimes over enthusiastic response to these novel therapeutic approaches.

The effects of anti-CD4 mAb on CD4+ T cell survival have also provided insights into the pharmacodynamic approach to T cell directed therapeutic studies. Studies of murine anti-CD4 Ab revealed CD4+ T cell depletion (hours to several months) irrespective of the antibody isotype while chimeric anti-CD47 and humanised anti-CDW52 (CAMPATH 1H)8 caused prolonged peripheral blood CD4+ T cell depletion out to five years. The dichotomy between clinical and biological effects of anti-CD4 treatment prompted pharmacodynamic studies of the synovial compartment. With chimeric α-CD4 mAb, cMT412, a reduction in the number of inflammatory cells and adhesion molecules was seen in the tissues that failed to correlate with clinical improvement.9 There were no significant changes in the proportion of the synovial CD4+ cells or CD45 RO memory or CD45 RA+ naive cells after treatment. An insufficient decrease in synovial CD4+ T cells and persistence of cytokines IL-1β and TNFα was cited to explain the discrepancy. Persistent synovial infiltration by CD4+ T cells was also observed during profound peripheral T cell depletion with CAMPATH-1H treatment.10 More recent, pharmacodynamic studies demonstrated a correlation between the clinical response and percentage of anti-CD4 mAb (M412) coated CD4+ lymphocytes in the synovial fluid.11 The data suggest that the lack of clinical benefit with anti-CD4 treatment probably reflects inadequate dosing or duration of treatment, or both. These results also underscore the importance of the synovium as a window for monitoring particularly when no association between clinical and peripheral biological responses is apparent.

The lack of clinical efficacy with anti-T cell mAb may also reflect the relatively short duration of mAb treatment. In the systemic lupus erythematosus mouse model only prolonged treatment with anti-CD4 mAb to modulate T cell function could abrogate the development of the disease.12 Recent data demonstrating resistance of memory CD4+ T cells to anti-CD4 treatment may also explain the lack of clinical benefit of mAb treatment in RA.13 That this concept may be relevant is suggested by the increased numbers of circulating phenotypically active CD45 RO CD4+ T cells observed in RA patients after CAMPATH-1H treatment.14 Finally, non-selective CD4+ T cell depletion may result in dysregulated immune function as CD4+ T cells subserve both helper and suppressor functions. This is supported by the finding of augmented rheumatoid factor production after anti-CD5 mAb treatment.15

The lack of clinical benefit with T cell depletion in RA is consistent with preclinical data in animal models of arthritis. In collagen induced arthritis profound depletion of CD4+ T cells with a heterologous anti-CD4+ mAb was insufficient to demonstrate a clinical effect. Indeed, studies showed that the Lyt-1+ T cells remaining after anti-CD4 mAb were CD4+ T cells exhibiting low surface CD4 expression. Thus, only treatment that eliminated virtually all CD4+ T cells as well as Ly 1+ T cells was clinical benefit observed suggesting that an

Abbreviations: RA, rheumatoid arthritis; RCT, randomised controlled trial; MMP, matrix metalloproteinase
extremely small number of CD4+ T cells are required to generate inflammation in CIA. Indeed, one recent report demonstrated the capability of a single CD4+ T cell to generate a delayed hypersensitivity response. In contrast with collagen induced arthritis, anti-CD4 mAb have been demonstrated to be effective in adjuvant arthritis in rats. This discrepancy underscores the limitations of animal models in preclinical studies. More relevant preclinical data may be provided by an immunodeficient in vivo mouse model using human CD4/HLA DR4/β2R transgenic mouse.

The prolonged T cell depletion observed with chimeric/humanised mAb is also consistent with previous murine data. These studies in mice have demonstrated the correlation of aging with more prolonged regeneration of the lymphocyte pool after depletion. Short-term depletion of CD4+ T cells with heterologous anti-CD4 mAb was observed in relatively young mice comparable in age to mice used in the collagen induced arthritis model of RA. In contrast, long term depletion of CD4+ cells was observed in older mice of an age comparable to that of mAb treated patients. In vitro data from murine studies also support the concept of enhanced T cell depletion with chimeric anti-CD4 mAb since augmented T cell cytotoxicity, ADCC and apoptosis was observed with chimeric anti-CD4 mAb compared with the heterologous counterpart. Studies of such a chimeric mAb in animal models of RA may have been predictive of the observed long term depletion in humans with chimeric/humanised mAb. Taken together, these data emphasise the need for preclinical studies to more closely approximate the human therapeutic paradigm.

The clinical consequence of prolonged T cell depletion has been instructive. Despite prolonged CD4 depletion to levels comparable to those in AIDS patients, serpids does not seem to be more prevalent. Whether the few lymphomas that occurred after CAMPATH-1H treatment were a direct result of the treatment, requires long term follow up studies. Although septic complications of CD4+ cell depletion with anti-CD4 mAbs seem rare, concern exists regarding the use of new therapeutic agents in patients with persistent CD4+ T cell lymphopenia. Such patients may not have the opportunity to participate in future trials of immunomodulatory agents until their CD4+ T cells normalise.

A number of alternative approaches to T cell depletion in RA have been developed and seem promising. The clinical benefit observed in NZB mouse model with F(ab)2 anti-CD4 mAb suggests the utility of non-depleting anti-CD4 mAb in autoimmune disorders.20 In RA, preliminary results of open label trials with a primitised IgG1 and humanised IgG421 non-depleting anti-CD4 mAb, suggest clinical benefit with only a transient reduction in CD4+ T cells. A RCT using the primitised mAb has confirmed these data.22 A second RCT was performed with primitised anti-CD4 mAb produced by a different manufacturing process resulted in reduced clinical efficacy and significant peripheral blood CD4+ T cell depletion. Both RCTs have been summarised recently.23 These data showed a dose dependent increase in peripheral blood CD4 T cell coating but a different pattern of CD4 depletion. Few patients in the first RCT had CD4 counts below 450/μm3 at the end of treatment while a substantial proportion of patients exhibited CD4 counts below this level in the second study. The mAb was produced by a different manufacturing process although both used similar Chinese hamster ovary cell lines. The most notable molecular difference between the anti-CD4 molecules was level of aggregate and non-glycosylated heavy chain. Comparisons in several in vitro and in vivo assays did not identify significant immunological differences. The clinical response was not correlated with CD4 depletion but was correlated with CD4+ T cell coating with the non-depleting anti-CD4 mAb. Of significance, one humanised IgG1 mAb (4162W94) resulted in substantial peripheral blood CD4+ T cell depletion/maintenance that correlated with clinical improvement.24 The mAb was well tolerated with no patients developing anti-idiotypic responses.

**TNF AS A TARGET**

An early approach to target TNF was the use of a recombinant fusion protein combining two extracellular domains of the 55 kDa human TNF receptor and one IgG1, heavy chain-R045–2081 (lenercept). A single dose IV study demonstrated clinical efficacy up to 28 days with a good safety profile.25 A three month study with monthly intravenous infusions also revealed efficacy associated with antibodies to lenercept in a proportion of patients.26 No influence on efficacy or safety was noted. Intravenous infusions up to one year showed a 50% drop out rate mainly for insufficient efficacy with a substantial clinical response in the completers. Serum antibodies were detected 60% of patients but demonstrated no influence efficacy or safety. A more modest effect was observed with lenercept produced by a different process.27 Studies of immunogenicity revealed anti-lenercept antibodies of IgM and IgG classes with the amount of IgG being dose dependent and amount of IgM correlating with rheumatoid factor.28 Anti-lenercept antibodies bound to the surface of human cells while inhibition studies revealed binding to Fc receptors rather than to TNFR55. No neutralising activity was detected. Lenercept given weekly by the subcutaneous route resulted in the generation of anti-lenercept antibodies that accelerated the clearance of lenercept with repeat dosing.29 There was no correlation between efficacy and lenercept or anti-lenercept antibodies. The development of lenercept was subsequently stopped. Clinical data remain unpublished.

**CYTOKINE ANTAGONISTS: IL4 AND IL10**

IL4 and IL10 defined initially as specific TH2 cytokines can suppress TH1 driven proinflammatory cytokines. IL10 is also produced by B cells, monocyte/macrophages and TH1-like cells and thus cannot be considered a specific TH2 product. Both cytokines have the capacity to inhibit inflammation and joint destruction in RA and animal models of RA.30 IL10 is found in RA synovium and has been shown to have a suppressive role in RA joints. In contrast, IL4 production in RA synovium is low.

A phase 1 dose escalating DB-RTC safety study of recombinant human IL4 (rHuIL4) was carried out in RA.31 Treatment with rhuIL4 did not produce significant clinical benefit in the short-term study but was well tolerated. Further development was halted.

rHuIL10 (given subcutaneously daily) was also evaluated in a DB-RTC phase I and cytokine response study in RA. During treatment a dose dependent thrombocytopenia was observed with a trend towards improvement in disease activity. Circulating levels of soluble TNFR (p55 and p75) as well as IL1ra showed a significant increase at the highest doses with trends toward decreased ex vivo production of IL1β and TNFα after PHA and LPS stimulation in rHuIL10 treated subjects. rHuIL10 was well tolerated. Lack of benefit in subsequent studies resulted in discontinued development.

**MATRIX METALLOPROTEINASE INHIBITORS**

Matrix metalloproteinases (MMPs) including the collagensases, stromelysins and gelatinases and membrane-type MMPs play an important part in RA.32 As MMPs seem to play such a fundamental part in the pathophysiology of RA and because destruction they cause is largely irreversible, specific therapeutic strategies have been developed to inhibit their action. Synthetic inhibitors were initially developed for use in oncology to inhibit spread of cancer cells, as well as angiogenesis which promotes their growth. Several potent broad spectrum MMP inhibitors including batimastat (MM94), marimastat (BB 2516), and CG 270323A have been developed. Most have been used for oncology indications. The safety profile improved with increased administration of marimastat demonstrated the most common drug related toxicity was musculoskeletal pain and stiffness initially involving peripheral small joints of the hands.
and spreading proximally in a time and dose dependent fashion. This side effect was reversible on drug withdrawal but the toxicity resulted in discontinuation of development. BAY 12–2566—an oral broad spectrum inhibitor with activity against stromelysin and gelatinase—demonstrated efficacy in models of osteoarthritis. It was used in osteoarthritis trials but discontinued. R0113, 0830 inhibited several MMPs by oral administration including collagenase 2 and 3 and was shown effective in a meniscus model of osteoarthritis. Clinical development was halted in phase II trials in osteoarthritis. The third promising oral MMP inhibitor developed for arthritis was Ro 32–3555 (Trocade). This hydroxamic acid was selective for collagenases 1, 2, and 3. It demonstrated efficacy in preserving cartilage in preclinical models of P acnes induced arthritis as well as models of osteoarthritis. Phase III clinical trials in RA were halted because of lack of efficacy at one year.

**SUMMARY**

Although a number of agents specifically developed for the treatment of RA have not continued in clinical development they have provided unique insights into study design, pharmacodynamics, immunobiology, and immunoactivity to biological agents.

**Author’s affiliations**

E Keystone, The Centre for Advanced Therapeutics, Mount Sinai Hospital and University of Toronto, Toronto, Canada

Correspondence to: Dr E Keystone, Mount Sinai Hospital, Room 1005, 600 University Avenue, Toronto, Ontario, Canada MSG 1X5; edkeystone@mtsinai.on.ca

**REFERENCES**


Treatments no longer in development for rheumatoid arthritis

E Keystone

Ann Rheum Dis 2002 61: ii43-ii45
doi: 10.1136/ard.61.suppl_2.ii43

Updated information and services can be found at:
http://ard.bmj.com/content/61/suppl_2/ii43

These include:

References
This article cites 28 articles, 3 of which you can access for free at:
http://ard.bmj.com/content/61/suppl_2/ii43#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/